CTLA4 and neoplasm: By using high-performance dimensional reduction methodology24–27, we further profile neoantigen-specific, tumour-infiltrating CD8+ T cells and assess the effects of anti-CTLA-4 and anti-PD-1 therapy on these cells and their peripheral counterparts.